1023 related articles for article (PubMed ID: 11058129)
21. Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5.
Kahata K; Hayashi M; Asaka M; Hellman U; Kitagawa H; Yanagisawa J; Kato S; Imamura T; Miyazono K
Genes Cells; 2004 Feb; 9(2):143-51. PubMed ID: 15009097
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel transcriptionally active domain in the transforming growth factor beta-regulated Smad3 protein.
Prokova V; Mavridou S; Papakosta P; Kardassis D
Nucleic Acids Res; 2005; 33(12):3708-21. PubMed ID: 15994459
[TBL] [Abstract][Full Text] [Related]
23. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein.
Shen X; Hu PP; Liberati NT; Datto MB; Frederick JP; Wang XF
Mol Biol Cell; 1998 Dec; 9(12):3309-19. PubMed ID: 9843571
[TBL] [Abstract][Full Text] [Related]
24. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling.
Felici A; Wurthner JU; Parks WT; Giam LR; Reiss M; Karpova TS; McNally JG; Roberts AB
EMBO J; 2003 Sep; 22(17):4465-77. PubMed ID: 12941698
[TBL] [Abstract][Full Text] [Related]
25. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.
Kuratomi G; Komuro A; Goto K; Shinozaki M; Miyazawa K; Miyazono K; Imamura T
Biochem J; 2005 Mar; 386(Pt 3):461-70. PubMed ID: 15496141
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
27. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.
Dennler S; Itoh S; Vivien D; ten Dijke P; Huet S; Gauthier JM
EMBO J; 1998 Jun; 17(11):3091-100. PubMed ID: 9606191
[TBL] [Abstract][Full Text] [Related]
28. The Smad3 linker region contains a transcriptional activation domain.
Wang G; Long J; Matsuura I; He D; Liu F
Biochem J; 2005 Feb; 386(Pt 1):29-34. PubMed ID: 15588252
[TBL] [Abstract][Full Text] [Related]
29. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling.
Hanyu A; Ishidou Y; Ebisawa T; Shimanuki T; Imamura T; Miyazono K
J Cell Biol; 2001 Dec; 155(6):1017-27. PubMed ID: 11739411
[TBL] [Abstract][Full Text] [Related]
30. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads.
Akiyoshi S; Inoue H; Hanai J; Kusanagi K; Nemoto N; Miyazono K; Kawabata M
J Biol Chem; 1999 Dec; 274(49):35269-77. PubMed ID: 10575014
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
32. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment.
Furumatsu T; Tsuda M; Taniguchi N; Tajima Y; Asahara H
J Biol Chem; 2005 Mar; 280(9):8343-50. PubMed ID: 15623506
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts.
Piek E; Ju WJ; Heyer J; Escalante-Alcalde D; Stewart CL; Weinstein M; Deng C; Kucherlapati R; Bottinger EP; Roberts AB
J Biol Chem; 2001 Jun; 276(23):19945-53. PubMed ID: 11262418
[TBL] [Abstract][Full Text] [Related]
34. Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner.
Verrecchia F; Vindevoghel L; Lechleider RJ; Uitto J; Roberts AB; Mauviel A
Oncogene; 2001 Jun; 20(26):3332-40. PubMed ID: 11423983
[TBL] [Abstract][Full Text] [Related]
35. Repression of Smad2 and Smad3 transactivating activity by association with a novel splice variant of CCAAT-binding factor C subunit.
Chen F; Ogawa K; Liu X; Stringfield TM; Chen Y
Biochem J; 2002 Jun; 364(Pt 2):571-7. PubMed ID: 12023901
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling.
Souchelnytskyi S; Tamaki K; Engström U; Wernstedt C; ten Dijke P; Heldin CH
J Biol Chem; 1997 Oct; 272(44):28107-15. PubMed ID: 9346966
[TBL] [Abstract][Full Text] [Related]
37. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.
Kawabata M; Inoue H; Hanyu A; Imamura T; Miyazono K
EMBO J; 1998 Jul; 17(14):4056-65. PubMed ID: 9670020
[TBL] [Abstract][Full Text] [Related]
38. Physical and functional interaction of SMADs and p300/CBP.
Pouponnot C; Jayaraman L; Massagué J
J Biol Chem; 1998 Sep; 273(36):22865-8. PubMed ID: 9722503
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II.
Wicks SJ; Lui S; Abdel-Wahab N; Mason RM; Chantry A
Mol Cell Biol; 2000 Nov; 20(21):8103-11. PubMed ID: 11027280
[TBL] [Abstract][Full Text] [Related]
40. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators.
Ghosh AK; Yuan W; Mori Y; Varga J
Oncogene; 2000 Jul; 19(31):3546-55. PubMed ID: 10918613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
